发布求助
文献互助 智能选刊 最新文献

Colorectal Cancer最新文献

筛选
英文 中文
Colorectal cancer incidence and clinicopathological features in northern Tunisia 2007–2009 2007-2009年突尼斯北部结直肠癌癌症发病率和临床病理特征
IF 4.2
Colorectal Cancer Pub Date : 2017-12-01 DOI: 10.2217/CRC-2017-0014
Houyem Khiari, M. Hsairi
{"title":"Colorectal cancer incidence and clinicopathological features in northern Tunisia 2007–2009","authors":"Houyem Khiari, M. Hsairi","doi":"10.2217/CRC-2017-0014","DOIUrl":"https://doi.org/10.2217/CRC-2017-0014","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"131-141"},"PeriodicalIF":4.2,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48260898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The impact of young adult colorectal cancer: incidence and trends in Colorado 年轻人癌症的影响：科罗拉多州的发病率和趋势
IF 4.2
Colorectal Cancer Pub Date : 2017-11-08 DOI: 10.2217/CRC-2017-0008
D. W. Sheneman, Jack L Finch, W. Messersmith, S. Leong, K. Goodman, S. Davis, W. Thomas Purcell, M. McCarter, C. Gajdos, J. Vogel, S. Eckhardt, Christopher H Lieu
{"title":"The impact of young adult colorectal cancer: incidence and trends in Colorado","authors":"D. W. Sheneman, Jack L Finch, W. Messersmith, S. Leong, K. Goodman, S. Davis, W. Thomas Purcell, M. McCarter, C. Gajdos, J. Vogel, S. Eckhardt, Christopher H Lieu","doi":"10.2217/CRC-2017-0008","DOIUrl":"https://doi.org/10.2217/CRC-2017-0008","url":null,"abstract":"Aim: Far less is known about colorectal cancer (CRC) incidence in individuals under the age of 50. This study examined CRC incidence in order to better understand the changing CRC population. Methods: This study analyzed 39,525 CRC cases from the Colorado Central Cancer Registry from 1992 through 2013. Age-adjusted incidence, observed and relative 5-year survival, and estimated annual percentage change was analyzed. Results: Age-adjusted rates averaging 1.7% per year were observed in the under-50 population, while falling on average 4.3% per year (p < 0.05) in the over-50 population. Average-adjusted incidence rose in males under 50 by 2.7% per year (p < 0.05). Conclusion: The absolute incidence of CRC continues to fall in Colorado, however incidence is rising in individuals under 50, particularly males.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"49-56"},"PeriodicalIF":4.2,"publicationDate":"2017-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43333452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Neuromodulation for low-anterior resection syndrome 神经调控治疗低位前切除综合征
IF 4.2
Colorectal Cancer Pub Date : 2017-11-01 DOI: 10.2217/CRC-2017-0012
N. McCawley, P. O'Connell
{"title":"Neuromodulation for low-anterior resection syndrome","authors":"N. McCawley, P. O'Connell","doi":"10.2217/CRC-2017-0012","DOIUrl":"https://doi.org/10.2217/CRC-2017-0012","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"45-48"},"PeriodicalIF":4.2,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43504440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy 广泛转移的her2阳性结肠癌对曲妥珠单抗治疗的长期反应
IF 4.2
Colorectal Cancer Pub Date : 2017-11-01 DOI: 10.2217/CRC-2017-0006
W. L. Gluck, Julie C. Martin, W. Edenfield, K. Chung, D. Arguello
{"title":"Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy","authors":"W. L. Gluck, Julie C. Martin, W. Edenfield, K. Chung, D. Arguello","doi":"10.2217/CRC-2017-0006","DOIUrl":"https://doi.org/10.2217/CRC-2017-0006","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"57-61"},"PeriodicalIF":4.2,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42764987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
New insights into colorectal cancer screening and early detection tests 结直肠癌筛查和早期检测试验的新见解
IF 4.2
Colorectal Cancer Pub Date : 2017-11-01 DOI: 10.2217/CRC-2017-0007
Seyed Mohammad Amin Kormi, Shima Ardehkhani, M. Kerachian
{"title":"New insights into colorectal cancer screening and early detection tests","authors":"Seyed Mohammad Amin Kormi, Shima Ardehkhani, M. Kerachian","doi":"10.2217/CRC-2017-0007","DOIUrl":"https://doi.org/10.2217/CRC-2017-0007","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"63-68"},"PeriodicalIF":4.2,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43537240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives 结直肠癌患者的免疫检查点抑制剂:错配修复缺陷和观点
IF 4.2
Colorectal Cancer Pub Date : 2017-06-21 DOI: 10.2217/CRC-2017-0004
R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André
{"title":"Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives","authors":"R. Cohen, M. Svrcek, A. Duval, Y. Parc, P. Österlund, T. André","doi":"10.2217/CRC-2017-0004","DOIUrl":"https://doi.org/10.2217/CRC-2017-0004","url":null,"abstract":"Harnessing the immune system to fight tumor cells is becoming a promising and innovative therapeutic strategy for a large spectrum of malignancies. The evaluation of immunotherapy in the context of colorectal cancers (CRCs) has brought to light mismatch repair deficiency as a major predictive biomarker for the efficacy of immune checkpoint blockade. In this review, we summarize the promising results of immune checkpoint inhibitors for patients with metastatic CRCs harboring mismatch repair deficiency, with special emphasis on further clinical development. Given the biological determinants of sensitivity to immune checkpoint blockade, we will also elucidate points that could unlock the potential of immunotherapy for patients with mismatch repair-proficient CRC.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"23-31"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41329789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Genomic profiling of colorectal cancers and the future of personalized treatment 结直肠癌的基因组分析和个性化治疗的未来
IF 4.2
Colorectal Cancer Pub Date : 2017-06-21 DOI: 10.2217/CRC-2016-0017
K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani
{"title":"Genomic profiling of colorectal cancers and the future of personalized treatment","authors":"K. Harada, D. Kaya, Shumei Song, H. Baba, J. Ajani","doi":"10.2217/CRC-2016-0017","DOIUrl":"https://doi.org/10.2217/CRC-2016-0017","url":null,"abstract":"New technologies have enabled faster, cheaper and more accurate genomic and other types of profiling. Therefore, treatment has become more customized according to molecular subtype. Here, we summarize the current status of genomic profiling for colorectal cancer (CRC) and discuss future directions. Recently, the CRC Subtyping Consortium classified CRC into four subtypes: CMS1, microsatellite instability immune (14%); CMS2, canonical (37%); CMS3, metabolic (13%); and CMS4, mesenchymal (23%). Testing for KRAS, NRAS and BRAF mutations, and microsatellite instability status in CRC has proven essential for treatment decisions. Tumor heterogeneity and the evolution of drug-resistant subclones after therapy should be further assessed and pursued. Patient-derived xenografts and liquid biopsies might facilitate the development of optimum and accurate personalized therapy regimens.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"11-22"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2016-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42731058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immune therapy in colorectal cancer 结直肠癌的免疫治疗
IF 4.2
Colorectal Cancer Pub Date : 2017-06-21 DOI: 10.2217/CRC-2017-0002
A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb
{"title":"Immune therapy in colorectal cancer","authors":"A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb","doi":"10.2217/CRC-2017-0002","DOIUrl":"https://doi.org/10.2217/CRC-2017-0002","url":null,"abstract":"The evidence that the immune system, when rightly stimulated, can eradicate cancer cells, combined with the latest knowledge about antitumor immunity, has led to recent progress in cancer immunotherapy. While infiltration of tumors with immune cells is described in advanced stage colorectal cancer (CRC), the first data concerning the clinical efficacy of immune-targeted therapies in CRC patients were disappointing. The evidence of tumor responses in CRC patients with microsatellite instability treated with immune checkpoint blockers has renewed the interest for research in the field of CRC immunotherapy. In this article, we briefly review the role of T lymphocytes infiltrating CRC tumors in order to introduce a brief history of CRC immunotherapy and then current trials involving immune-based strategies and particularly immune checkpoint blockers.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"1-10"},"PeriodicalIF":4.2,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45018124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. 在市区黑人糖尿病患者中使用二甲双胍对结直肠癌患者的生存益处
IF 4.2
Colorectal Cancer Pub Date : 2017-01-01 Epub Date: 2017-06-21 DOI: 10.2217/crc-2017-0001
Roger C Zhu, Kirk Rattanakorn, Steven Pham, Divya Mallam, Thomas McIntyre, Moro O Salifu, Irini Youssef, Samy I McFarlane, Shivakumar Vignesh
{"title":"Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population.","authors":"Roger C Zhu,&nbsp;Kirk Rattanakorn,&nbsp;Steven Pham,&nbsp;Divya Mallam,&nbsp;Thomas McIntyre,&nbsp;Moro O Salifu,&nbsp;Irini Youssef,&nbsp;Samy I McFarlane,&nbsp;Shivakumar Vignesh","doi":"10.2217/crc-2017-0001","DOIUrl":"https://doi.org/10.2217/crc-2017-0001","url":null,"abstract":"<p><p>We assessed the association of metformin use with survival in colorectal cancer in a population consists mostly of African-American and Afro-Caribbean patients. We identified 585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent of disease. Overall, DMs with metformin use (D+M+) have better overall survival than both DMs without metformin use (D+M∼) and nondiabetics (D∼M∼), with a mean survival of 109.9 months compared with 95.7 and 106.1 months, respectively (log-rank p < 0.05). The use of metformin shows significant reduction of risk of mortality compared with nonusers (hazard ratio: 0.34; 95% CI: 0.15-0.81; p = 0.01). Use of insulin and status of diabetes did not have a significant impact on overall cancer survival.</p>","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"33-41"},"PeriodicalIF":4.2,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc-2017-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35714554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Examining connections between screening for breast, cervical and prostate cancer and colorectal cancer screening. 研究乳腺癌、子宫颈癌和前列腺癌筛查与结直肠癌筛查之间的联系。
IF 4.2
Colorectal Cancer Pub Date : 2014-06-01 DOI: 10.2217/crc.14.18
Michael D Wirth, Heather M Brandt, Heather Dolinger, James W Hardin, Patricia A Sharpe, Jan M Eberth
{"title":"Examining connections between screening for breast, cervical and prostate cancer and colorectal cancer screening.","authors":"Michael D Wirth, Heather M Brandt, Heather Dolinger, James W Hardin, Patricia A Sharpe, Jan M Eberth","doi":"10.2217/crc.14.18","DOIUrl":"10.2217/crc.14.18","url":null,"abstract":"<p><strong>Aim: </strong>To compare participation in breast, cervical and prostate cancer screening with colorectal cancer (CRC) screening.</p><p><strong>Materials & methods: </strong>This random digit-dialed survey includes participants (aged 50-75 years) from South Carolina (USA). Past participation information in fecal occult blood test, flexible sigmoidoscopy, colonoscopy, mammography, clinical breast examination, Pap test, prostate-specific antigen and digital rectal examination was obtained.Adjusted odds ratios are reported.</p><p><strong>Results: </strong>Among European-American women, any cervical or breast cancer screening was associated with adherence to any CRC screening. Among African-American women, mammography was associated with adherence to any CRC screening. Digital rectal examination and prostate-specific antigen tests were associated with adherence to any CRC screening test among all men.</p><p><strong>Conclusion: </strong>Future research should explore approaches inclusive of cancer screening recommendations for multiple cancer types for reduction of cancer screening disparities.</p>","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"3 3","pages":"253-263"},"PeriodicalIF":4.2,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc.14.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32602914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信